Skip to main content
OpenTrials
Completed

NCT Number: NCT05147181

A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland

The main aim of this study is to learn about how many persons with HAE type I or type II are attack-free when treated with lanadelumab in real life, how many attacks occur and how many of these attacks need rescue treatment and about the nature of HAE attacks.

Participants will need to visit their doctor 5 times in total as part of this study. The visits are planned every 6 months. Participants will also be asked to fill out questionnaires as part of this study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hereditary Angioedema (HAE) Angioedema Angioedemas, Hereditary Cardiovascular Diseases Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Hereditary Complement Deficiency Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Immunologic Deficiency Syndromes Primary Immunodeficiency Diseases Skin Diseases Skin Diseases, Vascular Skin and Connective Tissue Diseases Urticaria Vascular Diseases

Age range

12 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Wielkopolskie Centrum Pulmonologii i Torakochirurgii im. Eugenii i Janusza Zeylandów/Szpital w Poznaniu, Poznan, Greater Poland Voivodeship, Poland

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Participant eligibility is determined according to the following criteria prior to entry into the study:

  • In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  • The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
  • HAE participant (aged greater than or equal to [>=] 12 years old.) qualified to treatment with lanadelumab in the NDP and receiving treatment according to the Summary of Product Characteristics for Takhzyro.
  • Male or female participants, aged >=12 years old.

Exclusion criteria

Any participant who meets any of the following criteria will not qualify for entry into the study:

  • Currently participates or plans to participate in any interventional clinical trial.
  • Any other reason that, in the Investigator's opinion, makes the participant unsuitable to participate in this study.

Participants should be included in the study only once. Data erroneously collected from participants for which written consent is not available, will not be included in or will be deleted from the database.

Treatment and study plan

Primary outcomes

  1. Change From Baseline in Total Number of HAE Attacks to 3 Months on Lanadelumab Therapy

    Time frame: Baseline up to 3 months

    Change from baseline (3 months period prior to qualification to NDP) to 3 months on lanadelumab therapy in the total number of HAE attacks will be analyzed using either a Poisson or negative binomial mixed effect model with period (pre or post qualification to NDP) as fixed effect and participant as a random effect. Choice of modelling method will depend on the degree of overdispersion in number of HAE attacks.

  2. Percentage of Participants Without HAE Attacks at Month 6

    Time frame: At Month 6

    Percentage of participants without HAE attacks will be analyzed and reported at Month 6.

  3. Percentage of Participants Without HAE Attacks at Month 12

    Time frame: At Month 12

    Percentage of participants without HAE attacks will be analyzed and reported at Month 12.

  4. Percentage of Participants Without HAE Attacks at Month 18

    Time frame: At Month 18

    Percentage of participants without HAE attacks will be analyzed and reported at Month 18.

  5. Percentage of Participants Without HAE Attacks at Month 24

    Time frame: At Month 24

    Percentage of participants without HAE attacks will be analyzed and reported at Month 24.

  6. Number of Participants Based on Type of Rescue Treatment Received

    Time frame: Up to 24 months

    Number of participants based on type of rescue treatment received will be analyzed and reported.

  7. Percentage of Participants With HAE Attacks Who Received Rescue Treatment

    Time frame: Up to 24 months

    Percentage of participants with HAE attacks who received rescue treatment will be analyzed and reported.

  8. Number of Participants Based on Severity of HAE Attacks

    Time frame: Up to 24 months

    Number of Participants based on severity of HAE Attacks i.e mild, moderate and severe will be analyzed. Mild means temporary or mild discomfort, moderate means activity limited mildly or moderately and some assistance may be needed and severe means activity considerably limited, assistance needed.

  9. Number of Participants Based on Anatomical Location of HAE Attacks

    Time frame: Up to 24 months

    Number of participants based on anatomical location of HAE attacks per body part(s) affected, such as peripheral (e.g., skin), abdominal, upper airway (e.g., larynx), other organs, duration of symptoms/ number of days with angioedema symptoms will be analyzed and reported.

  10. Time to First HAE Attack Requiring Rescue Treatment

    Time frame: Up to 24 months

    Kaplan-Meier analysis will be prepared for time to first HAE attack for which rescue treatment was used and time to first HAE attack after lanadelumab treatment discontinuation.

  11. Percentage of Participants With HAE Attacks Based on Visit to Healthcare Professional (HCP), Electronic Record (ER) or Hospitalizations

    Time frame: Up to 24 months

    Percentage of participants with HAE Attacks will be analyzed and reported based on Visit to HCP, access to an ER or hospitalizations.

  12. Duration of HAE Attack

    Time frame: Up to 24 months

    Duration of HAE Attack will be analyzed and reported.

Secondary outcomes

  1. Number of Participants Categorized Based on Lanadelumab Treatments Patterns

    Time frame: Up to 24 months

    Number of participants categorized based on lanadelumab treatments patterns will be analyzed and reported.

  2. Number of Participants Who Received Lanadelumab Treatment Prior to Discontinuation

    Time frame: Up to 24 months

    Number of participants who received lanadelumab treatment prior to discontinuation will be analyzed and reported.

  3. Number of Participants Based on Reason for Lanadelumab Treatment Discontinuation

    Time frame: Up to 24 months

    Number of participants based on reason for lanadelumab treatment discontinuation will be analyzed and reported.

  4. Change From Baseline in Work Productivity and Activity Impairment Questionnaire: General Health (WPAI:GH) at End of Landelumab Therapy

    Time frame: Up to 24 months

    The WPAI:GH is a generic questionnaire to measure the effect of general health and symptom severity on work productivity and regular activities during the past seven days. It can be self or interviewer-administered to adults aged 18 years or older. This six-item PRO instrument covers work (five items) and daily activities (one item) using yes/no or numerical answers (number of hours). It takes approximately two to three minutes to complete. WPAI:GH outcomes are expressed as impairment percentages. An overall work productivity score (health or symptom) [%WP], is calculated by multiplying the percentage of work time spent working (health or symptom) [% WTW] by the percentage productivity at work (health or symptom) [%PW]: %WP = %WTW*%PW. High scores indicate prolonged sick leave or impairment and decreased productivity. Change from baseline to the end of lanadelumab therapy in WPAI:GH will be modelled with a linear model using baseline total score and time of therapy as predictors.

  5. Change From Baseline in Angioedema Quality of Life (AE-QoL) at End of Landelumab Therapy

    Time frame: Up to 24 months

    Angioedema quality of life (AE-QoL) questionnaire was a self-administered validated angioedema disease-specific quality of life instrument. It consisted of 17 specific questions that were associated with work, physical activity, free time, social relations, and diet. Each of the 17 items had a 5-point response scale ranging from 1 (Never) to 5 (Very Often). The questionnaire was scored according to the developers' guidelines to produce a total score and 4 domain scores (functioning, fatigue/mood, fear/shame, nutrition). Raw domain scores (mean of the item scores within each scale) and the raw total score (mean of all item scores) were rescaled using linear transformations into final percentage scores ranging 0 to 100, based on the maximum possible score, where the higher the score the greater the QoL impairment. Change from baseline in AE-QOL at end of landelumab therapy will be analyzed.

Sponsors and collaborators

Lead sponsor

Takeda

Industry

Registry information

Official study title

Lanadelumab Treatment Outcomes in HAE Polish Patients Treated in the Scope of National Drug Program (NDP). Prospective, Multicenter Observational Study

Acronym: CHOPIN

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Dec 7, 2021
Registry last updated
Mar 31, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.